Vulvodynia (Investigational)
Highly investigational adjunct for chronic vulvodynia refractory to conventional therapy; no clinical study identified; pelvic floor PT, topical therapy, and TCAs remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for vulvodynia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is highly investigational, paraspinal placement only.
- What evidence exists?
- No published clinical study of leech therapy could be verified for this condition. Tier C (highly investigational). Evidence-based management per ACOG and ISSVD includes pelvic floor physical therapy (a cornerstone), topical lidocaine 5 percent or topical estrogen for hormonal-mediated vestibulodynia, tricyclic antidepressants (amitriptyline, nortriptyline), gabapentin or pregabalin, and selective surgical vestibulectomy for refractory provoked vestibulodynia. Cognitive behavioral therapy and sex therapy are valuable adjuncts.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the sacrum / lower back for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Worsening of vulvar pain in the first 24 hours
- Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
- Delay or replacement of pelvic floor physical therapy or evidence-based pharmacotherapy
- Dangerous mucosal contamination if any vulvar / vaginal placement is attempted
- Who should not consider this
- Patients who are pregnant
- Any consideration of vulvar, vaginal, or perineal placement (mucosal placement is absolutely contraindicated)
- Patients with active vulvovaginal infection (candidiasis, bacterial vaginosis, herpes) or dermatosis (lichen sclerosus, lichen planus, lichen simplex chronicus)
- Patients with untreated comorbid depression or anxiety contributing to pain perception
- Patients who have not engaged with pelvic floor physical therapy
- Patients on anticoagulants, with hemophilia, or with anemia
- What to ask your clinician
- Has my vulvodynia been classified (localized vs generalized, provoked vs spontaneous, primary vs secondary)?
- Have other causes been ruled out (lichen sclerosus, lichen planus, atrophic vulvitis, recurrent yeast / BV, infection, pudendal neuralgia)?
- Am I engaged with a pelvic floor physical therapist?
- Have I tried topical lidocaine, topical estrogen (if appropriate), TCAs, or gabapentinoids?
- If provoked vestibulodynia is refractory, am I a candidate for surgical vestibulectomy?
- Has the practitioner explained that NO vulvar / vaginal placement is permitted — only sacral / paraspinal?
- What is the practitioner's experience and Aeromonas-prevention plan?
- When to seek urgent care
- New severe vulvar pain with ulceration, blistering, or discharge (rule out herpes, candida, bacterial infection)
- Severe pelvic pain unrelated to typical vulvodynia
- Sudden urinary retention, severe dysuria, or hematuria
- Spreading redness, warmth, pus, or red streaks on the lower back (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for vulvodynia.
- No clinical study of leech therapy for vulvodynia was identified, so efficacy versus pelvic floor PT, topical lidocaine, TCAs, or gabapentinoids is unknown.
- Mechanism rationale (anti-inflammatory neuropathic modulation) does NOT establish clinical efficacy.
- Leech therapy is NEVER applied to the vulva, vagina, or perineum — those are absolute contraindications.
- Leech therapy is not a substitute for pelvic floor physical therapy or evidence-based pharmacotherapy.
Safety cross-references
Clinical Profile
- Category
- Gynecologic
- ICD-10
- N94.819, N94.818
- Safety tier
- High
Evidence Summary
Vulvodynia diagnosis follows ISSVD 2015 terminology (localized vs generalized, provoked vs spontaneous), and management per ACOG and ISSVD includes pelvic floor physical therapy, topical lidocaine or estrogen, tricyclic antidepressants, gabapentin, and selective surgical vestibulectomy. No clinical study of leech therapy for vulvodynia (of any design) was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov, the Baskova and Isakhanyan 2004 monograph, or English- and Russian-language web searches; use is investigational and mechanistic only, and the honest evidence grade is D. Vulvar leech application is not appropriate due to mucosal anatomy, and any neuropathic-pain-modulation rationale is unproven. Pelvic floor dysfunction is the dominant biomechanical contributor and requires pelvic PT.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Pregnancy
- Any vulvar, vaginal, or perineal placement (mucosal contraindication)
- Active vulvovaginal infection or dermatosis
- Untreated comorbid depression or anxiety
Related Conditions
Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational for non-specific chronic pelvic pain; the only clinical report located is an uncontrolled 60-woman series in which leeches were one part of multimodal care.
Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; no clinical study identified; AUA-guideline stepwise therapy remains primary.
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use proposed for non-suppurative lactational mastitis; no clinical study of leech therapy was identified.